Nitinol Implant helps repair irregular bone surfaces.November 13, 2007 -
With OSSArc(TM) Anatomic Residual Compression Implant, surgeon can secure legs of implant parallel to osteotomy or fusion interface. Sloping back creates low-profile construct that minimizes potential soft tissue irritation. Made of nitinol, which possesses shape memory and super-elastic properties, implant is inserted in malleable state at room temperature and then heated above body temperature. During process, alloy's structure transforms into state stronger than 316L SS.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
BioMedical Enterprises, Inc.
Texas Research Park
San Antonio, TX, 78245
USA
BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
SAN ANTONIO, Oct. 31 /-- BME (BioMedical Enterprises, Inc.), a privately held medical device company and leader in orthopaedic shape memory implant technology, today announced the November launch of the OSSArc(TM), the first nitinol implant adapted for irregular bone surfaces and metaphyseal anatomy.
The OSSArc(TM), an enhancement of BME's highly successful OSStaple(TM) implant, allows the surgeon to secure the legs of the implant parallel to the osteotomy or fusion interface while its unique sloping back creates a low profile construct that minimizes any potential soft tissue irritation by reducing the implant's prominence. The OSSArc(TM) is ideal for procedures, such as Akin osteotomies and Jones fractures in the foot and phalangeal and metacarpal fractures in the hand, that can be a challenge with other methods of fixation.
Made of nitinol, a biocompatible alloy possessing shape memory and super-elastic properties, the OSSArc(TM) implant is inserted while in its malleable state at room temperature. Using BME's patented OSSforce(TM) Implant Controller, the implant is safely heated above body temperature. During this process, the implant's legs close and its s-shaped back shrinks providing uniform compression while the alloy's structure transforms into a state approximately 20% stronger than 316L stainless steel. Due to nitinol's unique properties, the implant continues to maintain a compressive force over time through long-term active reduction.
BME recently received a patent award from the United States Patent and Trademark Office for 61 claims providing protection for their innovative OSSforce(TM) Implant Controller technology. The OSSArc(TM) Implants and the OSSforce(TM) Implant Controller will be showcased by BME at the Podiatry Institute's Annual Sanibel Conference being held November 1-3, 2007 in Fort Myers, Florida.
BME is a medical device company that addresses the changing needs in musculoskeletal medicine. BME focuses on minimally invasive orthopaedic instrumentation and implants that elicit a biologic response. BME's focus on memory metal internal fixation implants is changing the shape of orthopaedic medicine. Its specialized history of musculoskeletal research services will continue to produce unique, state of the art orthopaedic products that provide better outcomes for patients and more convenience to surgeons. For more information visit http://www.bme-tx.com/.
CONTACT: Eric Marcano, Marketing Manager of BioMedical Enterprises, Inc.
(BME), Tel: +1-800-880-6528, or Fax: 1-866-913-3977
Web site: http://www.bme-tx.com/
|
|
|
|
|
|
|
| 
